In the early days of the COVID-19 pandemic, pulmonologist Joseph Varon offered an opinion that made headlines around the world and went viral on social media. Varon was fighting two wars, he said: one against COVID and one against stupidity.
The world’s first “human challenge” trial in which volunteers were deliberately exposed to the coronavirus has found that symptoms had no effect on how likely an infected person is to pass the disease on to others.
People may be at increased risk for developing diabetes for up to a year after a diagnosis of COVID-19, according to two studies. Additionally, organ donation from dying donors with current or previous COVID-19 infection is likely safe, transplant teams from the United States and Italy will report at the April 2022 European Congress of Clinical Microbiology & Infectious Diseases meeting.
The emerging BA.2 form of the Omicron coronavirus variant does not seem to be any more severe than the original BA.1 form, an official of the World Health Organization said on Feb. 1.
The highly infectious Omicron coronavirus variant causes less severe disease than the Delta strain but it remains a “dangerous virus,” particularly for those who are unvaccinated, the head of the World Health Organization (WHO) said on January 12.
Two doses of the Pfizer Inc. and BioNTech SE COVID-19 vaccine are highly protective against a rare but often serious condition in children that causes organ inflammation weeks after COVID-19 infections, a U.S. Centers for Disease Control and Prevention report said on January 7.
British scientists will be studying whether higher doses of a cheap and widely used steroid called dexamethasone could work better for patients with severe COVID-19 compared to the standard low doses, they said on December 30/
Although there have been discussions about using different Covid-19 vaccines in combination, World Health Organization (WHO) chief scientist Soumya Swaminathan warned against it, calling it a “dangerous trend.”
Newly announced findings from a Phase III trial conducted by CytoDyn indicate that the use of the late-stage biotechnology company’s CCR5 antagonist candidate Vyrologix (leronlimab) was safe and improved the survival rate in critically ill hospitalized patients with coronavirus disease 2019.
A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.
